Serum IL-33 levels are raised in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis

Clinical Rheumatology

Volumn 30, Issue 6, 2011, Pages 825-830

  Yanaba, Koichi ^a   Yoshizaki, Ayumi ^b   Asano, Yoshihide ^c   Kadono, Takafumi ^c   Sato, Shinichi ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cytokine; Fibrosis; IL 33; Systemic sclerosis

Indexed keywords

INTERLEUKIN 33;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LONGITUDINAL STUDY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FIBROSIS; HUMANS; INTERLEUKINS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; VITAL CAPACITY; YOUNG ADULT;

EID: 79959580694     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1686-5     Document Type: Article

References (25)

1. White B (1996) Immunopathogenesis of systemic sclerosis. Rheum Dis Clin Nor Am 32:695-708
2. Sato S (1999) Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 11:503-507
3. Needleman BW, Wigley FM, Stair RW (1992) Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 35:67-72
4. Famularo G, Procopio A, Giacomelli R et al (1990) Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 81:368-372 (Pubitemid 20273657)
5. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328-332 (Pubitemid 27104098)
6. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275-284 (Pubitemid 43209303)
7. Molteni M, Della Bella S, Mascagni B et al (1999) Increased interferon-gamma (IFN-γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 116:164-168 (Pubitemid 29170020)
8. Grassegger A, Schuler G, Hessenberger G et al (1998) Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139:639-648 (Pubitemid 28474310)
9. Schmitz J, Owyang A, Oldham E et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-490 (Pubitemid 41587888)
10. Moussion C, Ortega N, Girard JP (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 3:e3331
11. O'Neill LA, Dinarello CA (2000) The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today 21:206-209 (Pubitemid 30259023)
12. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY (2007) IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 37:2779-2786 (Pubitemid 47578297)
13. Xu D, Jiang HR, Kewin P et al (2008) IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 105:10913-10918
14. Palmer G, Talabot-Ayer D, Lamacchia C et al (2009) Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 60:738-749
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
16. LeRoy EC, Krieg T, Black C et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202-205 (Pubitemid 18073738)
17. Steen VD, Powell DL, Medsger TAJ (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203 (Pubitemid 18088039)
18. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37:391-394 (Pubitemid 24093631)
19. Clements PJ, Lachenbruch PA, Seibold JR et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobeservar variability in 3 independent studies. J Rheumatol 20:1892-1896 (Pubitemid 24031593)
20. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27:645-653
21. Fleischmajer R, Perlish JS, Reeves JRT (1977) Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975-984
22. Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 18:9-17
23. Gillery P, Fertin C, Nicolas JF et al (1992) Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role fibrosis. FEBS Lett 302:231-234
24. Chizzolini C (1999) T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 21:431-450
25. Manetti M, Ibba-Manneschi L, Liakouli V et al (2010) The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 69:598-605